Statement: In the primary trial, Dasatinib, 70 mg, Twice Daily results in a better median PFS than Dasatinib, 100 mg, Daily.
Primary_evidence: Outcome Measurement:    Progression-free Survival   RECIST progression defined as 20% increase in the sum of longest diameters of target measurable lesions over the smallest sum observed, unequivocal progression of non-measurable disease, the appearance of any new lesion/site, death due to disease without prior documentation of progression and without symptomatic deterioration, development of one or more new bone lesions from baseline, or symptomatic deterioration related to disease progression. Time from date of registration to date of first documentation of progression or symptomatic deterioration, or death due to any cause. Patients last known to be alive and progression-free are censored at last date of contact.   Time frame: Up to 2 years Results 1:    Arm/Group Title: Dasatinib, 100 mg, Daily   Arm/Group Description: Dasatinib, 100 mg PO daily until progression of disease   Overall Number of Participants Analyzed: 41   Median (95% Confidence Interval)   Unit of Measure: weeks  10.3        (8.4 to 16.7) Results 2:    Arm/Group Title: Dasatinib, 70 mg, Twice Daily   Arm/Group Description: Dasatinib, 70 mg PO twice daily until progression of disease   Overall Number of Participants Analyzed: 38   Median (95% Confidence Interval)   Unit of Measure: weeks  15.3        (8.7 to 20.1)